Search Results

Discovery. David has over 20+ years of experience working in a drug discovery environment mainly in a specialist Discovery that he was awarded in 2020. discovery. " Dr. GPCR Unlock the Full Dr.

Aurélien Rizk is a scientist and entrepreneur in drug discovery. Before focusing on the development of innovative mathematical modeling and simulation methods for drug discovery, Dr. Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery Aurelien Rizk confirmed his attendance at the upcoming GPCR-Targeted Drug Discovery Summit in Boston.

drugs. GPCR x GeneTex partnership. the human nonsensory and orphan GPCRs. GPCR ecosystem Dr. GPCR Dr. GPCR is a nonprofit ecosystem dedicated to advancing GPCR-targeted drug discovery.

Can models predict drug outcomes? Jens Carlsson shares how GPCR modeling is moving from explanation to real prediction in drug discovery Bridging computation, chemistry, and pharmacology is key to speeding up drug discovery. discovery. science, and what that means for the future of drug discovery.

GPCR Ecosystem. partner, you'll gain trusted access to an engaged audience of academic researchers, biotech teams, and drug discovery innovators — without having to fight for attention." GPCR? GPCR platform as a valued partner ✓ Share insights on product launches, scientific discoveries, or customer

Falling in Love with GPCRs GPCR pharmacology captured his scientific curiosity. GPCRs were hot, then ignored. About Sokhom Pin Sokhom Pin is a receptor pharmacologist with over 20 years of drug discovery research He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general GPCR Podcast? Leave a Review.

discovery campaigns. I have extensive training in computer-aided drug design. discovery. GPCR Unlock the Full Dr. GPCR Podcast? Leave a Review.

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused spent significant time in the industry studying membrane proteins, antibodies, and HTS methods for drug discovery. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Podcast? Leave a Review.

and in vitro drug discovery. Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function and drug discovery of GPCRs and transporters. GPCR Ecosystem Unlock the Full Dr. GPCR Podcast? Leave a Review.

engaged in researching molecular mechanisms that govern human (patho-)physiology and their interplay with drugs I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets to create drugs with fewer adverse effects. I want to combine experimental approaches with data-driven discovery and adopt data science methodology GPCR Unlock the Full Dr.

Chris Langmead is Professor, Deputy Director, and Better Medicines Theme Leader of the Neuromedicines Discovery He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has He has published over 70 research articles, reviews and book chapters on drug discovery, which have been GPCR Ecosystem Unlock the Full Dr. GPCR Podcast? Leave a Review.

ABOUT THE GUEST Brian Arey is Director of Mechanistic Pharmacology within the Discovery and Optimization discovery across Wyeth and BMS. Drug discovery needs modulators more than it needs hammers Arey's philosophy of drug discovery is grounded Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular He continues to pioneer in drug discovery studying GPCRs and other target classes.

Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing She oversaw early discovery programs IL-23 p19 and IL23 p19/IL-17 bispecifics. She has extensive experience working with Biologics, and Antibody Drug Conjugates as well as experience GPCR Ecosystem Unlock the Full Dr. GPCR Podcast? Leave a Review.

Receptors in Complexes Behave Differently Than Receptors in Isolation Standard drug screens present a receptors, scaffold proteins, and cytoskeletal elements - and those interactions alter its conformation and drug-binding Understanding receptor complexes is where the next layer of selectivity and specificity in drug discovery Postdoc pivot: from GnRH receptors to arrestin interactions in Australia 12:47 The spin-out - how a discovery GPCR Podcast? Leave a Review.

Join us in strengthening the global GPCR community. Dr GPCR is a 501(c)(3) non-profit. 501(c)(3) Non-Profit Help Us Build a Global Home for GPCR Science GPCR University Premium to a colleague, mentee, or even yourself — the gift of cutting-edge GPCR education Help Us Close the Gap Between Academia and Biotech Together, we can accelerate GPCR discoveries and develop more effective drugs for everyone.

biology and for the identification of drug targets and future drug development. which has important functions in hemostasis, thrombosis, inflammation, and cancer and is an important drug She has made numerous important discoveries related to the mechanisms that control PAR1 signaling and GPCR Ecosystem Unlock the Full Dr. GPCR Podcast? Leave a Review.

His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and discovery. his mentors and significant discoveries related to allosteric receptors. discovery. Allosteric Modulation and Drug Discovery Yamina and Arthur delved into the complexities of protein-protein

Learn about course content, instructors, and how to advance your expertise in drug discovery. scientists and advancing GPCR discovery, together. GPCR University is a global platform where scientists share their knowledge, inspire discovery, and advance Together, we’re shaping the future of GPCR education — one course, one scientist, one discovery at a discovery.

His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and discovery. They also explored the significance of translating fundamental discoveries into clinical applications Translating Discovery Into Clinical Application Arthur and Yamina discussed the importance of translating They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and discovery. They also explored the significance of translating fundamental discoveries into clinical applications Translating Discovery Into Clinical Application Arthur and Yamina discussed the importance of translating They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

discovery logic and public health ethics, and illustrates how GPCR scientists reason about pharmacology Key Insights from the Conversation Challenge trials don't work without a reliable drug. Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

The experiment that mattered most was not a drug candidate or a clinical advance - it was a designed Selectivity without redesigning the drug PTH 1-34 activates both PTHR1 and PTHR2 with high potency, and spikes, bone biology, and why long-acting isn't always better 23:22 A detour into immunology and the discovery still a good drug target? I wasn't thinking this is going to be a new drug. I just thought of something and said, I wonder."

targets — a top-down rethink for drug discovery. << Back to podcast list Strategic Partner(s) GPCRs “We’re using outdated drugs. There are more elegant GPCR targets waiting to be explored.” He’s fascinated by transgenerational epigenetics — how parental pain, diet, or drug exposure can leave GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

, and how computational pipelines can accelerate GPCR signaling research and drug discovery. << Back protein families in pharmacology and drug discovery, yet many receptors remain poorly characterized discovery and pharmacological characterization. discovery and functional characterization. Discovery Computational models are fundamentally dependent on high-quality experimental data.

Traditional drug discovery efforts have focused on agonists and antagonists that bind to the orthosteric ubiquitous class of plasma membrane receptors and serve as targets for more than one-third of all prescribed drugs GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

GPCR Affiliate Program and earn commissions by helping connect the global GPCR community. Share our ecosystem, courses, and events to advance drug discovery together. Dr. GPCR community. GPCR brand ambassador affiliate program Who can be a Dr. GPCR ambassador? GPCR Ecosystem?

His current focus is to realise Antiverse’s mission: engineering the future of drug discovery." Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

Advance your GPCR research career with Dr. GPCR University. GPCR University Your professional home in GPCR science. Access the experts, the intelligence, and the community that accelerates your growth. 🔬 Discovery scientists in the GPCR field. Aside from his vast experience in drug development, not to mention his extensive publication record,

. << Back to podcast list Strategic Partner(s) Silvio Gutkind: When GPCRs Drive Cancer GPCRs are the most drugged protein family in medicine, but until recently their role in cancer was treated as marginal Non-canonical signaling opened a new drug target. "What the heck" moments define real discoveries. Two of Dr. GPCR Podcast? Leave a Review.

After running her own academic group in Graz, she spent six and a half years at Novo Nordisk in early drug discovery, focused on incretin receptors. With comorbidities and aging populations driving drug discovery, the one-receptor-one-drug frame is increasingly numbers miss what a ligand is really doing 16:40 — AI plus "real intelligence": functional data in drug GPCRs led Maria to Thue W.